ESTRO 2021 Abstract Book

S1018

ESTRO 2021

1 Tata Medical Center, Radiation Oncology, Kolkata, India

Purpose or Objective Definite concurrent chemoradiation is currently the standard of care for locally advanced unresectable esophageal cancer.A lot of heterogeneity exists in practicing concurrent chemoradiation approaches. Here we aim to find out the efficacy and toxicities of standard arm of SCOPE 1 protocol implemented in first 36

patients at our institute. Materials and Methods

This is a retrospective audit of 36 patients of unresectable esophageal cancer treated with concurrent chemoradiation based on standard arm of SCOPE1 protocol between January 2015 to June 2019 at our institute. The electronic hospital information system and oncology information system (ARIA, Varian Medical System, Palo Alto, USA) was queried to obtain information on patient characteristics and treatment delivery patterns. Results Out of 36 patients 35 had squamous cell carcinomas.25% of the patients belong to more than 70 years of age. 66.7% patients had T4 disease with 16 (44.4%) had N2 and N3 nodal disease at presentation. A total of 30 patients(83.3%) could not undergo surgery because of location and locoregional extent of the disease.The median follow up of the entire cohort was 10 months (range 3-51 months)and was 13 months (range 4-51 months) for the surviving patients.The median overall survival of the entire cohort was 28 months(range 15 months-NA). At a median follow up of 10 months the 2 year locoregional control rate and overall survival were 71.2%(95% CI- 48.5%-85.3%) and 57.4% (95%CI-29.6%-77.6%) respectively.On univariate analysis none of the prognostic variables had significant impact on locoregional control or overall survival. Grade 3 or more severe dysphagia and thrombocytopenia were most commonly observed and were seen in 22.2% and 19.4% cases respectively.A comparison between the present study and the standard arm of the SCOPE 1 study is presented in Table 1.

Conclusion SCOPE1 protocol has been validated for the first time in a different geographical and racial population .Implementation of standard arm of SCOPE 1 protocol in first 36 patients at our institute had shown encouraging outcomes with acceptable adverse effects. Our results are comparable with initial results of the standard arm of the original SCOPE 1 protocol widely practiced in the United Kingdom. PO-1234 Chemoradiation in unresectable non metastatic biliary cancers: an updated systematic review S. bisello 1 , S. Bisello 2 , D. Vallerossa 1,2 , A. Benini 1,2 , V. Panni 3 , F. Bertini 1,2 , A. Galuppi 1 , A. Guido 1 , G. Macchia 4 , F. Deodato 4,5 , S. Cilla 6 , V. Picardi 6 , F. Romani 7 , M. Buwenge 1,2 , A.G. Morganti 1,2 , S. Cammelli 1,2 1 Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 2 Department of Experimental, Diagnostic and Specialty Medicine - DIMES, Alma Mater Studiorum Bologna University, Bologna, Italy; 3 Department of Oncology and Radiotherapy, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy; 4 Radiation Oncology Unit, Gemelli Molise Hospital – Università Cattolica del Sacro Cuore, Campobasso, Italy; 5 Istituto di Radiologia, Università Cattolica del Sacro Cuore, Roma, Italy; 6 Medical Physics